170 related articles for article (PubMed ID: 25354083)
21. Cost-effectiveness of dual-energy X-ray absorptiometry plus antiresorptive treatment in Australian women with breast cancer who receive aromatase inhibitors.
Sowa PM; Downes MJ; Gordon LG
J Bone Miner Metab; 2017 Mar; 35(2):199-208. PubMed ID: 26969395
[TBL] [Abstract][Full Text] [Related]
22. TBS and BMD at the end of AI-therapy: A prospective study of the B-ABLE cohort.
María RS; Marta PM; Sonia S; Natalia GG; Tamara M; Ignasi T; Maria MG; Jaime RM; Adolfo DP; Joan A; Xavier N
Bone; 2016 Nov; 92():1-8. PubMed ID: 27519968
[TBL] [Abstract][Full Text] [Related]
23. Negative Impact of Aromatase Inhibitors on Proximal Femoral Bone Mass and Geometry in Postmenopausal Women with Breast Cancer.
Lee SJ; Kim KM; Brown JK; Brett A; Roh YH; Kang DR; Park BW; Rhee Y
Calcif Tissue Int; 2015 Dec; 97(6):551-9. PubMed ID: 26232103
[TBL] [Abstract][Full Text] [Related]
24. Aromatase inhibitor-related musculoskeletal symptoms: is preventing osteoporosis the key to eliminating these symptoms?
Muslimani AA; Spiro TP; Chaudhry AA; Taylor HC; Jaiyesimi I; Daw HA
Clin Breast Cancer; 2009 Feb; 9(1):34-8. PubMed ID: 19299238
[TBL] [Abstract][Full Text] [Related]
25. Effects of zoledronic acid on bone mineral density during aromatase inhibitor treatment of Korean postmenopausal breast cancer patients.
Lee SA; Hwang SH; Ahn SG; Lee HM; Jeong J; Lee HD
Breast Cancer Res Treat; 2011 Dec; 130(3):863-70. PubMed ID: 21861101
[TBL] [Abstract][Full Text] [Related]
26. AI-related BMD variation in actual practice conditions: A prospective cohort study.
Rodríguez-Sanz M; Prieto-Alhambra D; Servitja S; Garcia-Giralt N; Garrigos L; Rodriguez-Morera J; Albanell J; Martínez-García M; González I; Diez-Perez A; Tusquets I; Nogués X
Endocr Relat Cancer; 2016 Apr; 23(4):303-12. PubMed ID: 26911377
[TBL] [Abstract][Full Text] [Related]
27. Adjuvant aromatase inhibitors and bone health.
Chowdhury S; Pickering LM; Ellis PA
J Br Menopause Soc; 2006 Sep; 12(3):97-103. PubMed ID: 16953982
[TBL] [Abstract][Full Text] [Related]
28. Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer.
Ito K; Blinder VS; Elkin EB
J Clin Oncol; 2012 May; 30(13):1468-75. PubMed ID: 22370313
[TBL] [Abstract][Full Text] [Related]
29. Bone Density Screening in Postmenopausal Women With Early-Stage Breast Cancer Treated With Aromatase Inhibitors.
Stratton J; Hu X; Soulos PR; Davidoff AJ; Pusztai L; Gross CP; Mougalian SS
J Oncol Pract; 2017 May; 13(5):e505-e515. PubMed ID: 28267392
[TBL] [Abstract][Full Text] [Related]
30. Hormonal deprivation therapy-induced osteoporosis in postmenopausal women with breast cancer.
Ghazi M; Roux C
Best Pract Res Clin Rheumatol; 2009 Dec; 23(6):805-11. PubMed ID: 19945692
[TBL] [Abstract][Full Text] [Related]
31. Impact of chemotherapy followed by aromatase inhibitors on bone health of women with ER-positive early breast cancer in real world clinical settings in Greece: Results of the POCHARBI trial conducted by the Hellenic Society of Breast Surgeons.
Markopoulos C; Koukouras D; Venizelos V; Karyda I; Xepapadakis G; Misitzis J; Kalogerakos K; Poulakaki F; Natsiopoulos J; Zobolas V; Savidou C; Antonopoulou Z; Tzoracoleftherakis E
Breast; 2016 Jun; 27():27-34. PubMed ID: 27212697
[TBL] [Abstract][Full Text] [Related]
32. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer.
Crew KD; Greenlee H; Capodice J; Raptis G; Brafman L; Fuentes D; Sierra A; Hershman DL
J Clin Oncol; 2007 Sep; 25(25):3877-83. PubMed ID: 17761973
[TBL] [Abstract][Full Text] [Related]
33. Managing the risk of osteoporosis in women with a history of early breast cancer.
Ravdin PM
Oncology (Williston Park); 2004 Oct; 18(11):1385-90, 1393; discussion 1394. PubMed ID: 15609468
[TBL] [Abstract][Full Text] [Related]
34. [Effect of aromatase inhibitors on bone metabolism].
Folkestad L; Bjerregaard JK; Bjarnason NH; Brixen KT
Ugeskr Laeger; 2007 May; 169(19):1774-9. PubMed ID: 17537350
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness analysis of extended adjuvant endocrine therapy in the treatment of post-menopausal women with hormone receptor positive breast cancer.
Erman A; Nugent A; Amir E; Coyte PC
Breast Cancer Res Treat; 2014 Jun; 145(2):267-79. PubMed ID: 24771048
[TBL] [Abstract][Full Text] [Related]
36. Prevention of osteoporosis as a consequence of aromatase inhibitor therapy in postmenopausal women with early breast cancer: rationale and design of a randomized controlled trial.
Kilbreath S; Refshauge KM; Beith J; Ward L; Sawkins K; Paterson R; Clifton-Bligh P; Sambrook PN; Simpson JM; Nery L
Contemp Clin Trials; 2011 Sep; 32(5):704-9. PubMed ID: 21570487
[TBL] [Abstract][Full Text] [Related]
37. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group.
Reid DM; Doughty J; Eastell R; Heys SD; Howell A; McCloskey EV; Powles T; Selby P; Coleman RE
Cancer Treat Rev; 2008; 34 Suppl 1():S3-18. PubMed ID: 18515009
[TBL] [Abstract][Full Text] [Related]
38. Emerging bone health issues in women with breast cancer in Hawai'i.
Carney JF; Davis J
Hawaii Med J; 2007 Jun; 66(6):164-6. PubMed ID: 17621865
[TBL] [Abstract][Full Text] [Related]
39. Aromatase inhibitors in obese breast cancer patients are not associated with increased plasma estradiol levels.
Diorio C; Lemieux J; Provencher L; Hogue JC; Vachon E
Breast Cancer Res Treat; 2012 Nov; 136(2):573-9. PubMed ID: 23053662
[TBL] [Abstract][Full Text] [Related]
40. Androgens and musculoskeletal symptoms among breast cancer patients on aromatase inhibitor therapy.
Gallicchio L; Macdonald R; Wood B; Rushovich E; Helzlsouer KJ
Breast Cancer Res Treat; 2011 Nov; 130(2):569-77. PubMed ID: 21647676
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
